The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
Author(s): Young MS, Horn EJ, Cather JC
Affiliation(s): Modern Dermatology, A Baylor Health Texas Affiliate, Dallas, TX, USA.
Publication date & source: 2011-01, Expert Rev Clin Immunol., 7(1):9-13.
Publication type: Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial
The first biologic therapy for psoriasis was approved in 2003. Other approvals followed, including TNF-alpha inhibitors, and in addition to providing new treatment options that were greatly needed, these therapies increased our understanding of the immunopathogenesis of psoriasis. Clinical trial activity increased, but all biologic trials were placebo controlled with no active comparators. In 2009, ustekinumab, a new agent that targets the p40 subunit of cytokines IL-12 and IL-23, was approved. In 2010, the Active Comparator (CNTO1275/Enbrel) Psoriasis Trial (ACCEPT) was published, the first active comparator trial of psoriasis biologic agents, comparing ustekinumab and the TNF antagonist etanercept. Here, we describe the results of the ACCEPT trial and offer an expert commentary on the results and implications for psoriasis treatment and research.